Korea OKs Gilead’s Sovaldi, All Eyes On Pricing
This article was originally published in PharmAsia News
Executive Summary
South Korea has granted approval to Gilead’s Sovaldi as a therapy for adults with genotype 1, 2, 3 or 4 chronic hepatitis C in combination with other therapies. All eyes are now on whether all four genotypes will be covered by the national health insurance scheme and at what price the drug will be sold in the country, as the company negotiates for reimbursement with the government over the next few months.
You may also be interested in...
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Korea Govt Partners With J&J To Bring In Local JLABS Site
In collaboration with the national health ministry, J&J’s JLAB program is coming to South Korea as its third destination in Asia, underscoring the country’s increasing need to access multinationals’ know-how and its growing impact on the global biotech landscape and innovation.
Could ASEAN Become Next Priority For Korean Pharma Firms?
Southeast Asia has so far not been a priority market for South Korean pharma firms, largely because of challenges such as access and affordability for patients. But a Deloitte executive suggested at a recent seminar that technology-based medicines, for example using next-generation formulation technologies, could be an initial focus for Korean firms looking to enter the rapidly growing ASEAN grouping.